By Dr. Lei DengAssistant Professor/Medical OncologistThoracic, Head & Neck Medical OncologyUniversity of Washington/Fred Hutchinson Cancer Centerhttps://youtu.be/QVW-vify1x8Transcript:Dr. Deng: "Hi everyone! Welcome…
Author: Dr. Arya Mariam Roy from Roswell Park Comprehensive Cancer Center What are antibody drug conjugates (ADCs)? Antibody drug conjugates (ADCs)…
MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal…
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in…
Bellevue, WA - October 24, 2024 The Binaytara Foundation, a leading global cancer non-profit organization dedicated to improving access to…
ESMO 2023 Update - KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author:…
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung…
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng,…
LIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC Author: Dr. Anam Kamal Selpercatinib…
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III…